In 2025, pharma isn’t just experimenting with digital health anymore; it’s being reshaped by it. And according to Galen Growth’s Pharmaceutical Digital Health Innovation Index, the industry has officially reached a turning point.
Digital health in pharma is no longer a side project or a “nice-to-have.” It’s becoming the core engine for how pharma discovers, develops, and delivers care.
But not everyone is keeping up.
Using data from Galen Growth’s HealthTech Alpha platform, the report draws a sharp line between two camps.
On one side are the “digital leaders,” who are building real momentum. On the other hand are the “laggards,” who are chasing trends without meaningful impact. The gap between them is significant and growing.
The rise of Direct-to-Patient (DTP) pharma
One of the biggest shifts defining 2025 is pharma abandoning traditional marketing and going all-in on full-stack Direct-to-Patient (DTP) pathways.
Galen Growth found 94% of large pharma companies building or running a DTP initiative. A massive shift from traditional, intermediary-heavy models.
But the leaders are going further. The report highlights the rise of the “full-stack” DTP model, where companies don’t just offer an app or portal, but an end-to-end experience.
For example, platforms like LillyDirect or PfizerForAll that combine remote diagnosis, telehealth, digital pharmacies, and transparent pricing into a single ecosystem.
The payoff:
- Faster time-to-therapy (days instead of weeks)
- Fewer middlemen
- Stronger supply-chain integrity
- Better protection against counterfeit drugs
DTP has moved beyond convenience to become a strategic advantage.
AI: No longer just an experiment
If 2023–24 was about experimenting with AI, 2025 was about operationalizing it.
The Galen Growth Index shows that AI has now moved from drug discovery to deep integration across pharma. It’s being woven across the entire R&D lifecycle, from early research to post-market optimization.
But there’s a twist.
Clinical trials have emerged as the real bottleneck, eating up over half of all R&D costs.
And while 99% of clinical-stage funding now backs AI-powered ventures, investment still lags behind early discovery.
In other words, we’ve learned how to find molecules faster. Now, the challenge is proving that they work faster. The real test has shifted from finding drugs to testing them smarter.
The winners integrate, they don’t experiment
One of the report’s strongest insights is:
Companies pulling ahead aren’t using AI as a side tool; they’re rebuilding their operating models around it.
These leaders are:
- Designing synthetic trial protocols
- Using predictive toxicology to reduce late-stage failures
- Embedding AI directly into decision-making, not just analysis
The result is years shaved off development timelines. Instead of automating one step, they are compressing the entire process.
The evidence-driven “Drug-and-Digital” standard
In 2025, the “pill-only” prescription is officially outdated. The new standard is “drug-and-digital,” where treatments are paired with digital tools to prove real-world impact.
Here is why the shift is happening:
- Evidence is everything: High-quality, peer-reviewed studies now validate that these digital companions genuinely work in boosting patient adherence and improving outcomes (like glycemic control).
- The evidence gap: Pharma is prioritizing hard proof. 73% of pharma digital partnerships now require strong clinical validation, far higher than Big Tech (47%) or payors (43%).
- Breaking silos for results: Success isn’t about top-down mandates anymore. Real progress is happening where data scientists, clinicians, and product teams work side by side to build tools that meet both patient needs and regulatory requirements.
A concentrated leadership landscape
The Galen Growth data also reveals just how true digital innovation in pharma is still dominated by a select few.
The 25 power players:
- Just 25 companies account for 46% of all global digital health partnerships.
The 2025 leaderboard:
- AstraZeneca tops the Balanced Scorecard for the second year in a row.
- In the list of top performers, Pfizer, Eli Lilly, and Roche are all there.
- The major mover is Novartis, which jumped from 17th place into the top ten.
Where’s the focus:
- Oncology leads the charge with 36% of all partnerships.
- Neurology and cardiovascular disease follow as the other top therapeutic priorities.
Looking toward 2026: Performance over participation
As we look ahead, the era of scattered “ad hoc innovation” is over. Galen Growth predicts a decisive shift toward integrated platform strategies where results are the only metric that matters.
What comes next?
- ROI or nothing: Forget vague pilots. Boards and Business Development now expect a direct link between every digital partnership and tangible outcomes—faster pipeline velocity or significant cost savings.
- Scale beats experimentation: It is no longer about how many deals you sign. Success will be defined by scalability: how efficiently you can deploy and adapt these digital solutions across multiple brands and geographies.
- From pilot to pipeline for Generative AI: GPT-native workflows will move out of pilots. The new focus will be on building audit trails and ensuring regulatory-compliant implementation at scale.
In short, pharma’s digital future isn’t about trying more things; it’s about making fewer things work exceptionally well.
-By Alkama Sohail and the AHT Team
These insights were made possible by HealthTech Alpha’s data. For anyone in the healthtech space, this kind of intelligence is a strategic advantage.
We are HealthTech Alpha’s exclusive sales partner in India. Get in touch with us to explore how HealthTech Alpha’s data can support your growth.
